Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EFFORTLESS Trial Of Boston Scientific’s S-ICD Headlines HRS 2016

This article was originally published in Clinica

Executive Summary

Results from 985 patients in EFFORTLESS, the largest post-market registry of Boston Scientific’s S-ICD (subcutaneous ICD), support the technology as an option for a broad population of ICD candidates, according to Lucas V. A. Boersma, an electrophysiologist at St. Antonius Hospital in The Netherlands. He presented data from the registry on May 6 at the Heart Rhythm Society Scientific Sessions in San Francisco.


Related Content

St. Jude Pauses LEADLESS II Trial Of Nanostim Following Reports Of Lost Telemetry





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts